,0,1
0,impair,9.650382978723403
1,color blindness,9.0
2,french enterprises,9.0
3,choroidal neovascularization,9.0
4,patient enrollment,9.0
5,2a study,8.833333333333332
6,2a trial,8.773809523809524
7,trial,8.773809523809524
8,sustained expression,8.7
9,estate taxes,8.6
10,sh,8.407407407407408
11,clinical materials,8.376470588235295
12,macular degeneration,8.295566502463053
13,interest rates,8.272727272727273
14,executive officer,8.255952380952381
15,nervous system,8.23076923076923
16,service fees,8.209677419354838
17,financial officer,8.200757575757576
18,editing technology,8.192307692307693
19,therapeutic benefit,8.17142857142857
20,officer insurance premiums,8.147727272727273
21,accounting pronouncements,8.134146341463415
22,review committee,8.11111111111111
23,operating officer,8.089285714285715
24,additional funding,8.083216783216784
25,tax authorities,8.0625
26,market developments,8.042307692307691
27,product quantities,8.026178010471204
28,webster professor,8.0
29,accounting policies,7.977896341463415
30,unrealized losses,7.96875
31,transactions,7.964285714285714
32,research committee,7.887417218543046
33,toxicology lot production,7.875
34,administrative expense,7.874482758620689
35,substantial expenditures,7.855555555555555
36,tax positions,7.848214285714286
37,therapeutic targets,7.821428571428571
38,regulatory approval,7.811494252873564
39,additional billings,7.787874194770747
40,deprecation charges,7.775
41,visual outcomes,7.75
42,money market funds,7.7270903010033445
43,research,7.72075055187638
44,therapeutic material,7.699633699633699
45,consolidated statements,7.690301802503766
46,dilutive securities,7.684531590413943
47,deemed definite lived,7.654545454545454
48,traded securities,7.651851851851852
49,additional funding,7.6387723387723385
50,research budget,7.637417218543046
51,incremental expenses,7.625602409638555
52,investor relations,7.62202380952381
53,upfront payment,7.6089743589743595
54,financial instruments,7.603535353535354
55,owned subsidiary,7.6
56,additional funding,7.583216783216783
57,annapurna therapeutics,7.572811447811448
58,written notice,7.569444444444445
59,public offering,7.551818181818182
60,retinal diseases,7.535714285714286
61,preclinical data,7.534869976359339
62,production system,7.532786885245901
63,original award,7.511904761904763
64,administrative expense,7.506061705989111
65,consolidated statement,7.495558672276765
66,preclinical studies,7.494271685761047
67,regulatory approval,7.47816091954023
68,clinical trials,7.468666128544042
69,professional fees,7.464912280701755
70,preferred stock,7.463917525773196
71,cash flows,7.439075630252101
72,rise,7.434782608695652
73,fa cns,7.4298245614035086
74,programs,7.424242424242424
75,insurance policies,7.412043775190328
76,worldwide license,7.403049203049203
77,basis,7.3896103896103895
78,price allocation,7.384500745156483
79,income tax consequences,7.380681818181818
80,initial indication,7.375
81,projections,7.360160965794769
82,written notice,7.345000000000001
83,licensed products,7.343867272368161
84,financial statements,7.3386400234226326
85,facilities allocation,7.338636363636363
86,stock warrants,7.330584192439862
87,common stock,7.327012763868434
88,additional infrastructure,7.325641025641025
89,development timelines,7.320257570483815
90,regulatory approvals,7.2972085385878485
91,intellectual property,7.294485058829322
92,global market,7.292307692307692
93,master service agreement,7.279256707380728
94,initial payments,7.277665317139002
95,claims,7.272058823529411
96,financial interest,7.265151515151516
97,additional funds,7.260423634336679
98,obligations tables,7.25
99,price consideration,7.246670833133022
100,accounting policies,7.240191423430628
101,valuation model,7.238095238095238
102,commercial supply,7.226694915254237
103,fraction amount,7.21969696969697
104,product candidates,7.21565169468173
105,net loss,7.211695906432748
106,net loss,7.211695906432748
107,maintenance fees,7.208333333333334
108,substantial expenses,7.20615796519411
109,net losses,7.190972222222222
110,house manufacturing expertise,7.190058479532164
111,net sales,7.187739463601533
112,stockholder defendants,7.182539682539682
113,contract research,7.18153486560187
114,clinical studies,7.1666803784450845
115,toxicology studies,7.16520979020979
116,annual period,7.154069767441861
117,court approval,7.148484848484848
118,patent applications,7.138888888888888
119,pricing model,7.126984126984127
120,cash charge,7.121546894619917
121,patent rights,7.119509043927648
122,durable efficacy,7.1190476190476195
123,cash flow models,7.117647058823529
124,equity interests,7.115942028985508
125,fa systemic expired,7.11164274322169
126,development expense,7.109848688237632
127,license fee,7.10945945945946
128,maintenance fee,7.108333333333334
129,interest expense,7.102776533811016
130,milestone payments,7.092110538137525
131,contingent payments,7.085081585081586
132,party service providers,7.069677419354838
133,intellectual property,7.065461397357949
134,material production,7.056776556776557
135,research,7.054083885209714
136,leasing activities,7.053431372549019
137,additional personnel,7.0446886446886445
138,financial information,7.039380764163373
139,market demand,7.01958041958042
140,capital stock,7.009372071227741
141,compensation expense,6.9915120681090155
142,preclinical studies,6.969271685761047
143,milestone payments,6.967972607103042
144,event,6.966666666666667
145,contribution savings plan,6.962686567164179
146,allergy programs,6.95933014354067
147,balance sheet arrangements,6.957635467980295
148,color vision deficiency,6.955882352941177
149,employees,6.953125
150,substantive options,6.944278606965174
151,stock offering,6.932402374258044
152,impairment charge,6.929272970124746
153,balance sheet date,6.928877298045655
154,development expenses,6.927722725220409
155,identifiable assets,6.924151478773328
156,clinical trials,6.9135519279482125
157,written claim,6.910714285714286
158,interest rate yields,6.909090909090909
159,single digits,6.901086956521739
160,milestone payments,6.898238950928708
161,accounting standards,6.884146341463415
162,annapurna therapeutics,6.880503755503756
163,research fees,6.879724910850738
164,preclinical trials,6.877506871627812
165,liability insurance policies,6.866477272727273
166,future payments,6.855921338548457
167,regulatory agreements,6.848450774612694
168,preclinical studies,6.827605019094381
169,development services budget,6.823786982248521
170,stock units,6.821493283348953
171,gene therapy expertise,6.804891015417331
172,capital stock,6.79725085910653
173,sublicense fees,6.788732394366197
174,termination fee,6.787096774193548
175,rare diseases,6.785087719298245
176,quarterly amounts,6.782848730217152
177,development expense,6.773836243332265
178,conditional advance,6.765079365079365
179,money,6.756521739130434
180,based compensation,6.75259581195138
181,commercialization,6.7484002326934265
182,net cash,6.74727668845316
183,clinical trials,6.740492159883984
184,development milestone payments,6.740331017922991
185,lived assets,6.726709822685056
186,current liabilities,6.717234262125903
187,cash charges,6.713213561286584
188,preclinical proof,6.711854103343466
189,manufacturing facilities,6.703947368421053
190,common shares,6.692155067155067
191,milestone fees,6.6865357643758765
192,intangible assets,6.67257448433919
193,early adoption,6.669083826152258
194,early adoption,6.669083826152258
195,common stock,6.660346097201767
196,gene therapies program,6.654898785425101
197,separation agreements,6.646480331262939
198,amortization expense,6.644864075898559
199,patent rights,6.644099207862075
200,milestone payments,6.635253713093825
201,retrospective approach,6.618181818181818
202,early application,6.610377358490567
203,sales price,6.610157846675653
204,performance obligations,6.608722358722359
205,compensation expenses,6.60763171912688
206,product candidates,6.592122282917025
207,property rights,6.583848383266988
208,research period,6.583153652651573
209,financial information,6.5813240782206295
210,accounting pronouncements,6.578590785907859
211,preferred shares,6.57769370884125
212,lease agreement,6.56957928802589
213,cash flows cash,6.556722689075631
214,term a1at expression,6.55
215,manufacturing activities,6.533849329205367
216,additional shares,6.533488733488733
217,research period,6.525461344959266
218,biopharmaceutical company,6.524452234881682
219,interest income,6.51948051948052
220,commercialization milestone payments,6.518766257896694
221,research license fees,6.513543344669173
222,gene therapy products,6.513057012739955
223,retrospective approach,6.487500000000001
224,market data,6.486752136752137
225,early adoption,6.485750492818925
226,stage research programs,6.478326309452137
227,preclinical study,6.474483502929386
228,gene therapy,6.46301067353699
229,tax authorities,6.4625
230,research agreement,6.456996506568936
231,master services agreement,6.449579288025889
232,hereditary angioedema,6.444444444444445
233,reporting periods,6.417635658914729
234,license fees,6.414858520492324
235,purchase price,6.414803775459513
236,internal research,6.409395240521068
237,administrative expense,6.40478578892372
238,continued research,6.402568733694562
239,federal action,6.396480331262939
240,material breach,6.394871794871795
241,goodwill impairment,6.376949710904935
242,standard codification,6.366704480998298
243,development expense research,6.3656869594122565
244,consolidated complaint,6.364734299516908
245,fasb issued asu,6.3520564988290396
246,licensed product,6.336482460119917
247,recurring adjustments,6.328671328671329
248,amd program,6.3244444444444445
249,product candidates,6.317346609935967
250,product revenue,6.3162106902097666
251,aggregate amount,6.3077922077922075
252,stock options,6.304624704166942
253,product basis,6.304014927652384
254,contract manufacturing organization,6.301636444051304
255,cash flows,6.296218487394958
256,gene vectors development,6.287916536904391
257,reporting company,6.272715599424117
258,retrospective approach,6.261538461538462
259,invoice regeneron quarterly,6.253479853479854
260,intangible assets,6.238437193059042
261,disease indication,6.2265132408575035
262,acquisition,6.223529411764706
263,generate revenue,6.222236069569071
264,treatment options,6.222056384742952
265,stock options,6.216891784912283
266,forma results,6.214285714285714
267,equipment,6.214097496706192
268,equipment,6.214097496706192
269,drug development,6.206082064215734
270,product candidate,6.201178010471204
271,government agency securities,6.196296296296296
272,allergy license agreement,6.195705414152016
273,clinical trials,6.19290415466886
274,payment accounting,6.192574252350342
275,therapy programs,6.163636363636363
276,increased costs,6.158364661654135
277,net assets,6.146373700995549
278,development activities,6.13986541362107
279,reporting periods,6.121067031463748
280,fair values,6.119137149571932
281,development services,6.117904629307344
282,considered indefinite lived,6.113519813519813
283,related expenses,6.1128355787682755
284,stock options,6.108196132738369
285,transaction costs,6.0946736453201975
286,securities exchange act,6.091418247515809
287,interim periods,6.085677749360614
288,annapurna option,6.0672128259337565
289,remaining period,6.060022148394242
290,development programs,6.055104236422918
291,life,6.0549019607843135
292,business entities,6.030712530712531
293,management judgment,6.022901142573273
294,effective date,6.021241830065359
295,administrative expenses,6.0209054399415844
296,research terms,6.01075939360936
297,patent terms,6.00931731104145
298,regulatory goals,6.006366047745358
299,sell products,5.993190151911996
300,royalty payments,5.976923076923077
301,intangible assets,5.968029029793737
302,effective maturities,5.966666666666667
303,agreements university,5.9563944608492
304,estimated liability,5.95
305,fiscal years,5.947061191626409
306,year period,5.945736434108527
307,future payments,5.9434213385484576
308,licensed products,5.934031206794391
309,warrants,5.9
310,biotechnologies,5.898897058823529
311,operating expenses,5.895191154227299
312,assistance,5.874074074074074
313,significant judgments,5.858719784025718
314,credit losses,5.853365384615385
315,analysis,5.841463414634147
316,annapurna option,5.8172128259337565
317,rare diseases,5.816666666666666
318,annapurna options,5.807460425146992
319,aggregate stock,5.806012763868434
320,fair values,5.804851435286218
321,management,5.767083793399583
322,research activities,5.765848591092066
323,deferred revenue,5.752217553688142
324,expenses,5.730032478423356
325,sale securities,5.719247115968427
326,revenue recognition process,5.718253968253968
327,stock options,5.718044617586855
328,common stock,5.708607855892974
329,product sales,5.687347425763558
330,revenue recognition requirements,5.668803418803418
331,acquisition closing date,5.664002011060834
332,forma adjustments,5.660324749876989
333,financial assets,5.658072319837026
334,commercialization efforts,5.651503344373012
335,development expenses,5.649944947442631
336,operating results,5.646489104116223
337,lease obligations,5.6396103896103895
338,research costs,5.633472035818794
339,option exercise price,5.6071927818020075
340,rent expense,5.6050472747497215
341,development services unit,5.583786982248521
342,license agreement,5.552848271294874
343,stock options,5.5429787414340215
344,performance obligation,5.540540540540541
345,acquisition method,5.521022179363548
346,fair values,5.519137149571932
347,licensing revenue,5.511111111111111
348,fixed assets,5.510886172650879
349,fair values,5.504851435286218
350,financing arrangement,5.499351827845476
351,recorded revenue,5.49011111111111
352,marketable securities,5.483683683683683
353,acquisition activity,5.45102495543672
354,stock option plans,5.445091390667991
355,agreements regeneron,5.404013508468248
356,development costs,5.375888311152176
357,license agreement,5.362372080818683
358,stock option awards,5.343504089080689
359,financial liabilities,5.335933014354067
360,cornell,5.324452234881683
361,development milestones,5.290107328568867
362,deferred revenue,5.28015873015873
363,year performance period,5.266276974649068
364,executive officer,5.255952380952381
365,financing arrangement,5.227422003284072
366,earlier testing,5.171428571428572
367,significant estimates,5.166258496601359
368,services,5.166057692307692
369,early stage,5.160377358490566
370,balance sheet,5.157635467980295
371,company,5.155869997446986
372,written notice,5.125
373,ataxia license agreement,5.095705414152016
374,adequate funding,5.090909090909091
375,original award,5.083333333333334
376,option exercise period,5.077519379844961
377,incur substantial,5.055555555555555
378,consolidated complaint,5.053623188405797
379,termination costs,5.0424539170506915
380,purchase price,5.020864381520119
381,regenxbio,5.016210476639925
382,consolidated statements,5.012882447665056
383,goodwill impairment analysis,5.010079792205748
384,sublicense fees,5.0
385,company stock issuance,4.9815670395664435
386,accounting policies,4.977896341463415
387,compensation expense,4.958725182863114
388,approvals,4.9523809523809526
389,preclinical proof,4.911854103343465
390,administrative expense,4.874482758620689
391,severe allergy,4.868421052631579
392,regulatory authorities,4.844827586206897
393,professional fees,4.833333333333334
394,ceased conducting,4.833333333333334
395,licensed patent,4.830145719489982
396,consolidated statement,4.818139317438055
397,regulatory approval,4.811494252873564
398,clinical trials,4.808288770053476
399,interest expense,4.807210031347962
400,interest expense,4.807210031347962
401,public offering,4.801818181818182
402,increasing expenditures,4.8
403,milestone payments,4.79654403567447
404,intellectual property,4.769894894894895
405,fa cns,4.7631578947368425
406,adverse outcomes,4.75
407,owned subsidiaries,4.733333333333333
408,cash,4.7176470588235295
409,licensed technology,4.716897856242118
410,transactions,4.714285714285714
411,efficacy,4.714285714285714
412,combination service,4.709677419354838
413,therapy trials,4.704545454545455
414,therapeutic protein,4.696428571428571
415,gene therapy,4.69377990430622
416,activities,4.67843137254902
417,capital,4.666666666666667
418,accrued liabilities,4.6568264924606595
419,court approval,4.648484848484848
420,closing price,4.644640605296343
421,annual compensation,4.632575757575758
422,goodwill,4.628838335267783
423,material production,4.628205128205128
424,lawsuits,4.625
425,generally occurs,4.625
426,initial application,4.616666666666667
427,upfront payment,4.6089743589743595
428,stock price,4.605994028505436
429,financial instruments,4.603535353535353
430,charge equal,4.603070175438597
431,remains uncured,4.6
432,early adoption,4.585750492818924
433,financial statements,4.585016835016835
434,scientific meetings,4.583333333333334
435,manufacturing facilities,4.578947368421053
436,gene therapies,4.574898785425101
437,agent considerations,4.571428571428571
438,therapeutic levels,4.571428571428571
439,obligations,4.568181818181818
440,cash payments,4.566365007541478
441,tax position,4.5625
442,tax purposes,4.5625
443,company,4.560359570789019
444,publicly announced,4.555555555555555
445,substantial doubt,4.555555555555555
446,substantial damages,4.555555555555555
447,stock compensation,4.554826616682287
448,licensed product,4.550768174405631
449,fasb voted,4.535714285714286
450,clinical expenses,4.527072997873848
451,license fee,4.526126126126126
452,cash,4.525054466230937
453,service requirements,4.5173697270471465
454,funds,4.513729977116705
455,previously trading,4.5
456,final determination,4.5
457,minimum thresholds,4.5
458,scale production,4.5
459,united states,4.5
460,based approach,4.499453551912568
461,preclinical studies,4.494271685761047
462,product approval,4.492844677137871
463,administrative expenses,4.490602409638554
464,technology,4.487874194770747
465,development expense,4.4782697408692105
466,principally relating,4.475
467,losses,4.46875
468,credit losses,4.46875
469,based compensation,4.457029309488326
470,incur costs,4.455357142857142
471,options,4.452611940298508
472,related expenses,4.446168912101609
473,fa systemic,4.444976076555024
474,hereditary angioedema,4.444444444444445
475,tax services,4.4425
476,ongoing consideration,4.440092165898617
477,cash flows,4.439075630252101
478,accounting related,4.429712843926469
479,related stock,4.426150694902917
480,limited activity,4.425339366515837
481,rs1 gene,4.421052631578947
482,basis,4.41991341991342
483,cash charges,4.41764705882353
484,rare diseases,4.416666666666666
485,lower stock,4.4162984781541486
486,amounts,4.415584415584416
487,quarterly report,4.410256410256411
488,market activity,4.409954751131222
489,potentially revenue,4.407679738562091
490,exclusive license,4.403049203049203
491,product candidate,4.401178010471204
492,jointly owned,4.4
493,development payments,4.39250493096647
494,basis,4.3896103896103895
495,research fees,4.387417218543046
496,administration procedure,4.385964912280702
497,deferred taxes,4.385714285714286
498,separate recognition,4.375
499,initial indication,4.375
500,severe allergies,4.368421052631579
501,lived assets,4.358288770053476
502,benefits,4.35
503,amortization expense,4.349297573435504
504,regulatory functions,4.344827586206897
505,regulatory affairs,4.344827586206897
506,licensed products,4.343867272368161
507,fa program,4.3431578947368426
508,net cash,4.339869281045752
509,capital,4.333333333333334
510,remains outstanding,4.333333333333334
511,human primates,4.333333333333334
512,common stock,4.327012763868434
513,financial position,4.325757575757576
514,financial condition,4.325757575757576
515,clinical development,4.320257570483815
516,transaction price,4.319159836065573
517,securities,4.316296296296296
518,outstanding options,4.310945273631841
519,internal systems,4.3076923076923075
520,additional disclosures,4.307122507122507
521,complaint,4.3
522,restructuring charges,4.3
523,operating activities,4.292717086834735
524,market prices,4.292307692307692
525,market acceptance,4.292307692307692
526,market capitalization,4.292307692307692
527,securities,4.291418247515809
528,revenue,4.290032679738562
529,financial information,4.285757575757575
530,income approach,4.284848484848485
531,preclinical development,4.284212514163414
532,licensed patents,4.274590163934427
533,adverum biotechnologies,4.273897058823529
534,biotechnologies,4.273897058823529
535,insurance coverage,4.272727272727273
536,insurance carriers,4.272727272727273
537,undivided interest,4.272727272727273
538,therapy,4.272727272727273
539,expenses,4.270602409638554
540,separation agreements,4.265527950310559
541,significant influence,4.262295081967213
542,rent payments,4.261217948717949
543,average period,4.260022148394242
544,misleading statements,4.2592592592592595
545,related information,4.255566502463054
546,related costs,4.2509236453201975
547,stock offering,4.250584192439863
548,ophthalmic diseases,4.25
549,ophthalmologic diseases,4.25
550,contractual obligations,4.25
551,ocular diseases,4.25
552,diseases,4.25
553,wet amd,4.2444444444444445
554,additional collaboration,4.242307692307692
555,license,4.23482177830004
556,institutional stockholders,4.23015873015873
557,financial assets,4.229500891265597
558,potential license,4.227821041380364
559,avalanche biotechnologies,4.227678571428571
560,consideration,4.225806451612903
561,variable consideration,4.225806451612903
562,patents,4.225
563,net consists,4.222222222222222
564,impairment related,4.220939636791412
565,canceled prior,4.220000000000001
566,settled prior,4.220000000000001
567,intangible assets,4.218029029793736
568,product candidates,4.21565169468173
569,forma results,4.214285714285714
570,operating lease,4.214285714285714
571,net loss,4.211695906432748
572,annual periods,4.208333333333334
573,net property,4.208333333333334
574,annual tests,4.208333333333334
575,administration expenses,4.203233988585923
576,safety issues,4.2
577,assets,4.199309817971075
578,cash,4.196594427244582
579,concept data,4.194444444444445
580,data package,4.194444444444445
581,technology platforms,4.1923076923076925
582,net sales,4.187739463601533
583,entirety,4.186633039092055
584,losses,4.183035714285714
585,related research,4.182983721006101
586,judgments,4.1826923076923075
587,superior court,4.181818181818182
588,annapurna stockholder,4.1812770562770565
589,related services,4.175566502463054
590,record charges,4.175
591,aggregate intrinsic,4.171428571428571
592,aggregate balances,4.171428571428571
593,day notice,4.166666666666667
594,defendants,4.166666666666666
595,debt financings,4.166666666666666
596,internal medicine,4.15954415954416
597,manufacturing activities,4.157378740970072
598,period,4.155038759689923
599,concept studies,4.153846153846153
600,qualified expenses,4.150602409638554
601,travel expenses,4.150602409638554
602,marketable securities,4.15035035035035
603,patents,4.15
604,exercise price,4.149828440716736
605,exercise price,4.149828440716736
606,indefinite lived,4.146853146853147
607,ipr&amp,4.146382978723404
608,corporate bonds,4.142857142857142
609,cash,4.138055222088836
610,company,4.13159509202454
611,unrecognized stock,4.130584192439862
612,material respects,4.128205128205128
613,aggregate costs,4.126785714285714
614,license extends,4.126126126126126
615,irrevocable license,4.126126126126126
616,net assets,4.125965537730243
617,primary focus,4.125
618,primary reasons,4.125
619,commercial paper,4.125
620,option,4.124031007751938
621,interim reporting,4.121067031463748
622,patent rights,4.119509043927648
623,stage milestones,4.119047619047619
624,operating assets,4.118029029793735
625,cash equivalents,4.117647058823529
626,existing cash,4.117647058823529
627,cash receipts,4.117647058823529
628,additional indication,4.117307692307692
629,royalty term,4.116666666666667
630,revenue,4.115010946907499
631,revenue contract,4.113562091503268
632,related disclosures,4.110381317277869
633,stock options,4.10819613273837
634,planned levels,4.105263157894736
635,planned upgrade,4.105263157894736
636,personnel expenses,4.102983362019507
637,government grants,4.1
638,significant agreements,4.099251603706343
639,similar securities,4.0962962962962965
640,benchmark securities,4.0962962962962965
641,treasury securities,4.0962962962962965
642,agency securities,4.0962962962962965
643,development expenses,4.094389391887075
644,payment obligations,4.093822843822844
645,additional indications,4.092307692307692
646,interest income,4.090909090909091
647,exclusive rights,4.0908765652951695
648,options,4.086307592472421
649,retinal delivery,4.085714285714285
650,manufacturing processes,4.078947368421053
651,activities,4.078431372549019
652,payment,4.078272604588394
653,single injection,4.075
654,human patients,4.0701754385964914
655,current guidance,4.070135746606335
656,significant judgments,4.069987389659521
657,digit royalty,4.066666666666666
658,amounts,4.063424947145878
659,public company,4.0634132738427216
660,development activity,4.06143404107205
661,primarily related,4.053142260038812
662,drug administration,4.052631578947368
663,awards,4.05112205801861
664,current assets,4.050802139037433
665,lease term,4.05
666,liability,4.045566502463054
667,patents,4.045566502463054
668,effect,4.044444444444444
669,financing activities,4.04394861392833
670,net income,4.040404040404041
671,research expenses,4.038019628181601
672,sufficient funds,4.034782608695652
673,development programs,4.034696073157612
674,net decrease,4.02991452991453
675,related project,4.028899835796388
676,payment schedule,4.0256410256410255
677,development program,4.023786982248521
678,development activities,4.02221835479754
679,modified award,4.020833333333334
680,incurred prior,4.010697674418605
681,accrued expenses,4.007745266781411
682,annual report,4.003205128205129
683,vegf program,4.003076923076923
684,accounting identified,4.0008130081300814
685,menlo park,4.0
686,accumulated deficit,4.0
687,unmet medical,4.0
688,clause,4.0
689,significantly revises,4.0
690,temporarily impaired,4.0
691,prices,4.0
692,curves,4.0
693,prepayment spreads,4.0
694,northern district,4.0
695,purported class,4.0
696,san mateo,4.0
697,damages,4.0
698,insured retention,4.0
699,readily measurable,4.0
700,item,4.0
701,top,4.0
702,retinoschisis,4.0
703,strategic partnerships,4.0
704,discernible pattern,4.0
705,agree annually,4.0
706,profitable depends,4.0
707,laboratory supplies,4.0
708,highly uncertain,4.0
709,historical experience,4.0
710,readily apparent,4.0
711,larger scale,4.0
712,ticker symbol,4.0
713,commenced trading,4.0
714,people,4.0
715,combination attribution,4.0
716,informational purposes,4.0
717,anticipated synergies,4.0
718,achievable subsequent,4.0
719,collaboration targets,4.0
720,banque publique,4.0
721,laboratory space,4.0
722,office space,4.0
723,march2016,4.0
724,practical expedients,4.0
725,frequent injections,4.0
726,induce stable,4.0
727,technical corrections,4.0
728,chiron corporation,4.0
729,teen percentage,4.0
730,involuntary petition,4.0
731,office building,4.0
732,definitive documentation,4.0
733,positive control,4.0
734,leading crispr,4.0
735,exchange act,3.995121951219512
736,financial assistance,3.992424242424242
737,product sales,3.9916952518505147
738,advance payments,3.9915750915750916
739,comprehensive loss,3.9894736842105263
740,loss contingency,3.9894736842105263
741,stock plans,3.9877270495827197
742,genetic medicine,3.985185185185185
743,adverum,3.984313725490196
744,overhead expenses,3.9839357429718874
745,common stockholders,3.9821428571428577
746,common equity,3.9790372670807455
747,events,3.9782608695652173
748,product development,3.969964992719725
749,reporting unit,3.9693023255813955
750,increasing losses,3.96875
751,regulatory milestones,3.9638752052545154
752,license agreements,3.9630826478652565
753,savings plan,3.9626865671641793
754,annual basis,3.9615800865800868
755,historical information,3.96
756,current requirements,3.9547511312217196
757,patent claims,3.952614379084967
758,personnel,3.9523809523809526
759,specific personnel,3.9523809523809526
760,development,3.943786982248521
761,assay development,3.943786982248521
762,discontinue development,3.943786982248521
763,development initiatives,3.943786982248521
764,cornell informed,3.942857142857143
765,closing date,3.9404725992961285
766,action,3.938423645320197
767,research term,3.9374172185430463
768,hae program,3.9371428571428573
769,patients,3.936842105263158
770,manufacturing process,3.93609022556391
771,life,3.9327868852459016
772,foreseeable future,3.9322033898305087
773,future grants,3.9322033898305087
774,future periods,3.9322033898305087
775,future partners,3.9322033898305087
776,stock modifications,3.930584192439863
777,effective immediately,3.9285714285714284
778,impairment,3.925373134328358
779,2016 primarily relates,3.924242424242424
780,primarily relates,3.924242424242424
781,assets,3.9241514787733274
782,authoritative guidance,3.9230769230769234
783,vegf,3.9230769230769234
784,interim periods,3.9117647058823533
785,year license,3.906126126126126
786,identical assets,3.9037433155080214
787,similar assets,3.9037433155080214
788,single digits,3.9010869565217394
789,extension fee,3.9
790,shareholder notice,3.9
791,development costs,3.8991441251056633
792,future sales,3.8977206312098187
793,values,3.8962623951182307
794,financial liabilities,3.8959330143540667
795,sales organization,3.894088669950739
796,acquisition closing,3.892760180995475
797,based process,3.889929742388759
798,capital resources,3.8888888888888893
799,updated research,3.8874172185430464
800,research institutions,3.8874172185430464
801,stock awards,3.886139747995418
802,indemnification obligations,3.8829966329966332
803,operating facility,3.8809523809523814
804,executive officers,3.880952380952381
805,services,3.88
806,equity securities,3.87890499194847
807,future period,3.8779398239390357
808,full term,3.868181818181818
809,drug application,3.8666666666666667
810,wet age,3.861111111111111
811,revenue recognition,3.8611111111111107
812,business model,3.85971685971686
813,future adoption,3.8575765241588664
814,hae,3.857142857142857
815,related management,3.856172563069115
816,product revenue,3.845622454915649
817,alternative transaction,3.84375
818,partially offset,3.84
819,low single,3.8397058823529413
820,single unit,3.835
821,administered intravitreally,3.8333333333333335
822,research period,3.8331536526515735
823,outstanding shares,3.8290598290598292
824,efforts,3.8275862068965516
825,potential commercialization,3.82391713747646
826,business strategies,3.821621621621622
827,future research,3.8196206083735547
828,products,3.819277108433735
829,products,3.819277108433735
830,taxable income,3.8181818181818183
831,continuing decrease,3.8076923076923075
832,fair values,3.804851435286218
833,line basis,3.803246753246753
834,process development,3.8009298393913777
835,modification accounting,3.8008130081300813
836,accompanying notes,3.8
837,exchange ratio,3.8
838,exchange commission,3.8
839,periods,3.8
840,thereto,3.8
841,convertible notes,3.8
842,weill cornell,3.8
843,material breach,3.7948717948717947
844,average assumptions,3.7904761904761908
845,based awards,3.788342440801457
846,stockholders,3.7857142857142856
847,services,3.7847619047619045
848,year deferral,3.7800000000000002
849,calendar year,3.7800000000000002
850,product basis,3.7794247637179574
851,fiscal years,3.773148148148148
852,development efforts,3.7713731891450726
853,research services,3.7674172185430463
854,unobservable inputs,3.7666666666666666
855,conditional advance,3.765079365079365
856,low teens,3.764705882352941
857,proprietary vectors,3.7564102564102564
858,pretax basis,3.7532467532467533
859,respective fair,3.7514917514917516
860,lease liability,3.75
861,section,3.75
862,section,3.75
863,section,3.75
864,durable anti,3.75
865,collaboration partner,3.75
866,collaboration,3.75
867,costs,3.7460548172757475
868,purchase approximately 9,3.745454545454545
869,process research,3.7445600756859037
870,test goodwill,3.743243243243243
871,goodwill,3.743243243243243
872,additional time,3.7423076923076923
873,patients,3.736842105263158
874,cash milestones,3.7366946778711485
875,asu retains,3.734375
876,exclusive option,3.734287418008348
877,significant amount,3.7319920516641827
878,applicable period,3.7314507198228126
879,material effect,3.7282051282051283
880,financing arrangement,3.7274220032840724
881,year period,3.7257364341085273
882,actual acquisition,3.723529411764706
883,disclosures,3.7195767195767195
884,granted annapurna,3.718544137022398
885,terminate early,3.7183483729833195
886,current liabilities,3.7172342621259027
887,commercial sale,3.7151639344262293
888,single vector,3.715
889,leases,3.7142857142857144
890,evidence,3.7142857142857144
891,primarily due,3.7140974967061924
892,executive employees,3.709077380952381
893,potential effect,3.7016949152542376
894,generation,3.7
895,license agreement,3.695705414152016
896,common shares,3.6921550671550674
897,common shares,3.6921550671550674
898,estimated loss,3.689473684210526
899,factors,3.6875
900,company patent,3.6871506475800953
901,sale securities,3.686460230722526
902,considered preliminary,3.6809523809523808
903,acquisition costs,3.6788865546218488
904,commercialization costs,3.677579365079365
905,total intrinsic,3.675
906,share data,3.6711886304909562
907,goodwill impairment,3.6686163775716016
908,differ materially,3.666666666666667
909,scalable baculovirus,3.666666666666667
910,grade baculovirus,3.666666666666667
911,values,3.6594202898550723
912,cornell university,3.6571428571428575
913,estimated costs,3.6553571428571425
914,recorded expenses,3.6546024096385543
915,million relating,3.654584120982987
916,fixed assets,3.6537433155080214
917,indemnification agreements,3.6517713365539453
918,contractual maturities,3.6484848484848484
919,claims,3.6470588235294117
920,claims,3.6470588235294117
921,implied fair,3.645431145431145
922,employee share,3.643410852713178
923,aggregate amount,3.641125541125541
924,vector optimization,3.6399999999999997
925,regeneron,3.6380952380952385
926,model,3.638095238095238
927,research collaboration,3.6374172185430464
928,agreements,3.6369565217391306
929,table,3.6363636363636367
930,table,3.6363636363636367
931,excluded warrants,3.6347826086956525
932,material default,3.628205128205128
933,subsequent indication,3.625
934,business combinations,3.621621621621622
935,diligence milestones,3.619047619047619
936,development portfolio,3.6104536489151875
937,target development,3.6104536489151875
938,annapurna series,3.609848484848485
939,annapurna holds,3.609848484848485
940,future exercise,3.6066219944816713
941,amounts,3.6060606060606064
942,deferred revenue,3.6051587301587302
943,research,3.6017029328287604
944,research licenses,3.6017029328287604
945,rent,3.601232394366197
946,cumulative effect,3.6
947,observable inputs,3.6
948,contingencies collaborations,3.6
949,bpi france,3.6
950,ophthalmic indications,3.6
951,address unmet,3.6
952,angiogenic effect,3.6
953,sufficient quantity,3.6
954,full year,3.598181818181818
955,comparable securities,3.596296296296296
956,unvested rsus,3.595238095238095
957,litigation,3.5882352941176467
958,annapurna options,3.5874604251469924
959,collaboration agreements,3.5869565217391304
960,significant impact,3.5848757271285034
961,sales milestones,3.584564860426929
962,vector development,3.5837869822485207
963,competing technologies,3.583333333333333
964,innovative technologies,3.583333333333333
965,1 securities,3.583138401559454
966,million fee,3.579584120982987
967,debilitating disease,3.576923076923077
968,net increase,3.5722222222222224
969,underwriting discounts,3.571428571428571
970,mutually agreed,3.571428571428571
971,liabilities,3.5701754385964914
972,noncurrent liabilities,3.5701754385964914
973,activity,3.5700280112044815
974,lease agreement,3.56957928802589
975,collaboration revenue,3.5694444444444446
976,collaboration products,3.569277108433735
977,exclusivity obligations,3.5681818181818183
978,combined entities,3.565982404692082
979,development milestones,3.5628346012961396
980,rsus,3.5610766045548656
981,management,3.5606060606060606
982,necessarily indicative,3.5555555555555554
983,regeneron,3.5547619047619046
984,line results,3.55
985,amount,3.5486443381180224
986,viral vectors,3.5480769230769234
987,litigation costs,3.54359243697479
988,fair statement,3.5432806077967367
989,automatically terminated,3.541666666666667
990,option,3.539331554200025
991,equity awards,3.5381642512077294
992,company expenses,3.532197501663094
993,numerous risks,3.5294117647058822
994,inherent risks,3.5294117647058822
995,combined total,3.513709677419355
996,development agreement,3.5133662702744104
997,a1at deficiency,3.5058823529411764
998,derived principally,3.5
999,legal proceedings,3.5
1000,asserted actions,3.5
1001,actual results,3.5
1002,historical results,3.5
1003,anticipated results,3.5
1004,effort,3.5
1005,offsetting adjustment,3.5
1006,control premium,3.5
1007,open ind,3.5
1008,originally established,3.5
1009,average number,3.4994708994708996
1010,fractional shares,3.4957264957264957
1011,acquisition date,3.4947712418300654
1012,company,3.490290744198453
1013,acquisition method,3.488235294117647
1014,wamd therapies,3.4871794871794872
1015,1 prices,3.486842105263158
1016,lowest level,3.486842105263158
1017,ten years,3.4814814814814814
1018,stockholders,3.4813664596273295
1019,tier,3.4787644787644787
1020,events,3.4782608695652173
1021,subsequent events,3.4782608695652173
1022,4 million related,3.4751506234460408
1023,services,3.47375
1024,3 million ratably,3.47370176804181
1025,0 million ratably,3.47370176804181
1026,proprietary vector,3.473333333333333
1027,life,3.466666666666667
1028,company,3.463562305139294
1029,company,3.463562305139294
1030,plan,3.4626865671641793
1031,licensing agreements,3.4619565217391304
1032,company,3.4605424604455925
1033,company,3.4605424604455925
1034,license,3.4594594594594597
1035,term investments,3.459090909090909
1036,employees stock,3.4587091924398625
1037,options,3.4576119402985075
1038,laboratory equipment,3.4565217391304346
1039,revenue,3.455808080808081
1040,costs,3.455357142857143
1041,annapurna transaction,3.453598484848485
1042,considered level,3.4535087719298243
1043,considered level,3.4535087719298243
1044,prior quarter,3.450769230769231
1045,fully recoverable,3.4444444444444446
1046,bankruptcy proceedings,3.4444444444444446
1047,fully impaired,3.4444444444444446
1048,successful development,3.443786982248521
1049,accelerated vesting,3.4437340153452682
1050,years,3.4380032206119164
1051,sublicenses,3.4375
1052,potential effects,3.435028248587571
1053,inserm transfert,3.4347826086956523
1054,acceptable terms,3.431034482758621
1055,liabilities,3.427318295739348
1056,impairment indicators,3.425373134328358
1057,issuance costs,3.424744897959184
1058,target basis,3.41991341991342
1059,collaboration target,3.416666666666667
1060,defined period,3.412403100775194
1061,assets,3.4077433155080215
1062,development plan,3.4064735494127
1063,directors,3.4051851851851853
1064,option period,3.4031007751937983
1065,company,3.402003255289846
1066,revenues,3.4018181818181823
1067,impairment,3.395961369622476
1068,annapurna stockholders,3.395562770562771
1069,bonuses,3.393939393939394
1070,month anniversary,3.392857142857143
1071,recorded research,3.3914172185430465
1072,level,3.3905854207711794
1073,revenue agreement,3.389023732470334
1074,expected volatilities,3.3846153846153846
1075,annapurna entered,3.3817783094098885
1076,company,3.38159509202454
1077,company,3.38159509202454
1078,company,3.38159509202454
1079,company,3.38159509202454
1080,company records,3.38159509202454
1081,company,3.38159509202454
1082,company,3.38159509202454
1083,company,3.38159509202454
1084,company,3.38159509202454
1085,company,3.38159509202454
1086,company,3.38159509202454
1087,company,3.38159509202454
1088,company,3.38159509202454
1089,time stock,3.3805841924398625
1090,measurements,3.375
1091,move forward,3.375
1092,judgments,3.3701923076923075
1093,party,3.3600000000000003
1094,post acquisition,3.3598930481283427
1095,company options,3.3592070323230474
1096,research plan,3.3501037857072253
1097,increase significantly,3.35
1098,million relates,3.3462507876496534
1099,multiple deliverables,3.3461538461538463
1100,consulting costs,3.3442460317460316
1101,commercialization milestones,3.3412698412698414
1102,adopt asu 2014,3.334375
1103,annapurna acquisition,3.333377896613191
1104,active markets,3.3333333333333335
1105,continuing pre,3.333333333333333
1106,manner,3.333333333333333
1107,corporate sources,3.333333333333333
1108,conditional advances,3.3274853801169595
1109,risk factors,3.3238636363636367
1110,negative impact,3.32258064516129
1111,million stock,3.3101683134228495
1112,regeneron challenges,3.3047619047619046
1113,pending litigation,3.302521008403361
1114,administration treatment,3.297076023391813
1115,entity,3.2941176470588234
1116,project management,3.293939393939394
1117,acquisition agreement,3.293108699790596
1118,leases,3.288732394366197
1119,full amount,3.287878787878788
1120,core principle,3.2857142857142856
1121,requires substantially,3.2834008097165994
1122,payment,3.2793723689246077
1123,part,3.2777777777777777
1124,twelve months,3.2758620689655173
1125,consecutive months,3.2758620689655173
1126,time payment,3.2756410256410255
1127,fund research,3.272032603158431
1128,effective date,3.2712418300653594
1129,impairment analysis,3.2668365489625044
1130,term nature,3.2605263157894733
1131,0 million received,3.2585314894040396
1132,post annapurna,3.246212121212121
1133,treatment burden,3.2444444444444445
1134,issuance date,3.2406295851674
1135,combined companies,3.2387096774193544
1136,editas elects,3.236842105263158
1137,editas challenges,3.236842105263158
1138,amortized based,3.2327868852459014
1139,industry standard,3.2325581395348837
1140,share awards,3.232299741602067
1141,fourth quarter,3.230769230769231
1142,advm,3.229166666666667
1143,diligently proceed,3.2222222222222223
1144,regenxbio agreements,3.221571906354515
1145,tiered royalties,3.21875
1146,determined based,3.2164603546336568
1147,company,3.214928425357873
1148,ind meeting,3.2142857142857144
1149,valued primarily,3.212121212121212
1150,impairment evaluation,3.2110874200426442
1151,innovative nature,3.2105263157894735
1152,date,3.2087418300653594
1153,time period,3.195736434108527
1154,standalone fair,3.193050193050193
1155,distribution infrastructure,3.1904761904761907
1156,information,3.1895081967213113
1157,days,3.1818181818181817
1158,estimated fair,3.178764478764479
1159,inherent uncertainties,3.1764705882352944
1160,based expire,3.1756440281030445
1161,pay cornell $13,3.175
1162,successfully develop,3.1724137931034484
1163,company,3.1673093777388255
1164,assets,3.161807831637054
1165,future advm,3.161370056497175
1166,vegf,3.1556350626118066
1167,ceased marketing,3.1538461538461537
1168,total fair,3.1537644787644785
1169,company,3.153524916585943
1170,advance annapurna,3.152705627705628
1171,considered probable,3.151851851851852
1172,measurement period,3.145736434108527
1173,earlier terminated,3.1416666666666666
1174,recognize revenue,3.140873015873016
1175,adjusted pursuant,3.1367521367521367
1176,complete development,3.1223584108199494
1177,valuation hierarchy,3.111111111111111
1178,company exercises,3.1088678192972674
1179,actual timing,3.108695652173913
1180,customer contracts,3.107142857142857
1181,share attributable,3.1017441860465116
1182,administered directly,3.1
1183,editas medicine,3.0886939571150096
1184,3 inputs,3.086842105263158
1185,employees,3.0836805555555555
1186,editas agreements,3.0737986270022883
1187,research,3.071627744858836
1188,3 liabilities,3.057017543859649
1189,conditions,3.0524296675191813
1190,regeneron exercises,3.032034632034632
1191,million offset,3.019584120982987
1192,pipeline products,3.0192771084337346
1193,liabilities,3.010175438596491
1194,subjects,3.0101010101010104
1195,goodwill,3.0013077593722755
1196,legal actions,3.0
1197,step process,3.0
1198,shares,2.9997264957264957
1199,advancing advm,2.998397435897436
1200,disclosure requirements,2.9951923076923075
1201,million decrease,2.9872764286752944
1202,million decrease,2.9872764286752944
1203,million decrease,2.9872764286752944
1204,company,2.98159509202454
1205,company,2.98159509202454
1206,business circumstances,2.97456279809221
1207,directors,2.973917579551382
1208,ava,2.970550576184379
1209,discount rate,2.9696969696969697
1210,applicable country,2.9327731092436977
1211,operations,2.9136484940907357
1212,aav vector,2.9066666666666663
1213,estimates,2.9039634146341466
1214,country basis,2.900305576776165
1215,required vote,2.8961748633879782
1216,company,2.88559509202454
1217,company,2.88559509202454
1218,company,2.88559509202454
1219,company,2.88559509202454
1220,company,2.88159509202454
1221,company,2.88159509202454
1222,company,2.88159509202454
1223,amended agreement,2.880690399137001
1224,annapurna included,2.863579828132067
1225,party files,2.8600000000000003
1226,company,2.8431335535630016
1227,company option,2.838959433109811
1228,fully paid,2.8383838383838382
1229,company,2.8260395364689845
1230,entire company,2.8260395364689845
1231,circumstances,2.823529411764706
1232,equipment depreciation,2.816521739130435
1233,company,2.8026477236034872
1234,lives,2.7846153846153845
1235,company,2.78159509202454
1236,company,2.775534485963934
1237,held invalid,2.761904761904762
1238,operations,2.7479508196721314
1239,management,2.7442795299938156
1240,company,2.7230585066586865
1241,company,2.714928425357873
1242,expect general,2.7145135566188197
1243,maximum,2.6923076923076925
1244,scope improvements,2.678571428571429
1245,condensed,2.6774193548387095
1246,million shares,2.6753106167094822
1247,annapurna subject,2.6563601127554617
1248,company,2.639659608153572
1249,company,2.639659608153572
1250,initiate,2.6363636363636362
1251,company,2.635326435308122
1252,2016 increased,2.6315789473684212
1253,result,2.6288377192982457
1254,written,2.625
1255,effective january,2.611111111111111
1256,5 million allocated,2.6006367525619343
1257,funding,2.590909090909091
1258,calculated fair,2.584027636659216
1259,holder,2.5714285714285716
1260,company,2.565268561412295
1261,company,2.5634132738427216
1262,fasb,2.5357142857142856
1263,expense,2.5344827586206895
1264,million increase,2.529584120982987
1265,million increase,2.529584120982987
1266,million increase,2.529584120982987
1267,million increase,2.529584120982987
1268,million increase,2.529584120982987
1269,regents,2.5162790697674415
1270,fees,2.5
1271,maintenance,2.5
1272,additional,2.4923076923076923
1273,excluded form,2.4824016563147
1274,generate,2.4705882352941178
1275,lived,2.4545454545454546
1276,payments,2.448717948717949
1277,trials,2.4318181818181817
1278,higher,2.4285714285714284
1279,compensation,2.4242424242424243
1280,gene,2.4210526315789473
1281,provided,2.4074074074074074
1282,fee,2.4
1283,ava,2.390151515151515
1284,clinical,2.376470588235294
1285,toxicology,2.375
1286,long,2.3684210526315788
1287,allocation,2.3636363636363638
1288,developing ava,2.3484848484848486
1289,milestone,2.347826086956522
1290,preclinical,2.3404255319148937
1291,amended december,2.338138138138138
1292,royalties,2.335029069767442
1293,outstanding,2.3333333333333335
1294,retrospective,2.3333333333333335
1295,limited,2.3076923076923075
1296,patent,2.3055555555555554
1297,operations,2.300728597449909
1298,related,2.2955665024630543
1299,contract,2.2941176470588234
1300,market,2.292307692307692
1301,fiscal 2015,2.2916666666666665
1302,fiscal 2016,2.2916666666666665
1303,exclusive,2.276923076923077
1304,therapy,2.272727272727273
1305,insurance,2.272727272727273
1306,interest,2.272727272727273
1307,significant,2.262295081967213
1308,statements,2.259259259259259
1309,recently,2.25
1310,model,2.238095238095238
1311,central,2.230769230769231
1312,consideration,2.225806451612903
1313,net,2.2222222222222223
1314,prior,2.22
1315,annual,2.2083333333333335
1316,wholly,2.2
1317,definite,2.2
1318,warrants,2.2
1319,judgment,2.2
1320,totaling,2.2
1321,common,2.1964285714285716
1322,data,2.1944444444444446
1323,000 beginning,2.1739130434782608
1324,beginning,2.1739130434782608
1325,aggregate,2.1714285714285713
1326,closing,2.169230769230769
1327,rare,2.1666666666666665
1328,defendants,2.1666666666666665
1329,therapies,2.1538461538461537
1330,studies,2.1538461538461537
1331,entirety,2.1538461538461537
1332,053 studies,2.1538461538461537
1333,expenses,2.1506024096385543
1334,current,2.1470588235294117
1335,focused,2.142857142857143
1336,informed,2.142857142857143
1337,accounting,2.1341463414634148
1338,stock,2.1305841924398625
1339,material,2.128205128205128
1340,license,2.126126126126126
1341,commercial,2.125
1342,offering,2.12
1343,cash,2.1176470588235294
1344,adverum,2.1176470588235294
1345,expertise,2.111111111111111
1346,review,2.111111111111111
1347,granted,2.108695652173913
1348,planned,2.1052631578947367
1349,potential,2.1016949152542375
1350,government,2.1
1351,securities,2.096296296296296
1352,units,2.090909090909091
1353,programs,2.090909090909091
1354,004 programs,2.090909090909091
1355,permitted,2.0833333333333335
1356,issued,2.081967213114754
1357,issued 14,2.081967213114754
1358,program,2.08
1359,manufacturing,2.0789473684210527
1360,received,2.0789473684210527
1361,activities,2.0784313725490198
1362,disease,2.076923076923077
1363,single,2.075
1364,obligations,2.0681818181818183
1365,royalty,2.066666666666667
1366,statement,2.064516129032258
1367,requires,2.0526315789473686
1368,term,2.05
1369,recognition,2.0416666666666665
1370,&amp,2.04
1371,based,2.0327868852459017
1372,product,2.026178010471204
1373,payment,2.0256410256410255
1374,acquired,2.020408163265306
1375,observable,2.0
1376,models,2.0
1377,normal,2.0
1378,outcomes,2.0
1379,announced,2.0
1380,valuation,2.0
1381,nasdaq,2.0
1382,assigned,2.0
1383,pro,2.0
1384,professor,2.0
1385,exchanged,2.0
1386,drug,2.0
1387,agency,2.0
1388,allocating,2.0
1389,standards,2.0
1390,periods,2.0
1391,lease,2.0
1392,testing,2.0
1393,treat,2.0
1394,federal,2.0
1395,loss,1.9894736842105263
1396,property,1.9861111111111112
1397,options,1.9776119402985075
1398,losses,1.96875
1399,considered,1.9666666666666666
1400,sales,1.9655172413793103
1401,financing,1.9655172413793103
1402,information,1.96
1403,due,1.9565217391304348
1404,costs,1.9553571428571428
1405,personnel,1.9523809523809523
1406,period,1.945736434108527
1407,development,1.9437869822485208
1408,future,1.9322033898305084
1409,organization,1.9285714285714286
1410,adoption,1.9253731343283582
1411,impairment,1.9253731343283582
1412,vectors,1.9230769230769231
1413,interim,1.911764705882353
1414,provide,1.9047619047619047
1415,assets,1.9037433155080214
1416,elect,1.9
1417,life,1.9
1418,equal,1.894736842105263
1419,pricing,1.8888888888888888
1420,research,1.8874172185430464
1421,services,1.88
1422,application,1.8666666666666667
1423,identified,1.8666666666666667
1424,plans,1.8571428571428572
1425,university,1.8571428571428572
1426,accrued,1.8571428571428572
1427,process,1.8571428571428572
1428,discounted,1.8571428571428572
1429,hae,1.8571428571428572
1430,approximates,1.8571428571428572
1431,medicine,1.8518518518518519
1432,transaction,1.84375
1433,offset,1.84
1434,combined,1.8387096774193548
1435,agreements,1.8369565217391304
1436,proprietary,1.8333333333333333
1437,infrastructure,1.8333333333333333
1438,filing,1.8333333333333333
1439,proceeds,1.8333333333333333
1440,efforts,1.8275862068965518
1441,accelerated,1.826086956521739
1442,digits,1.826086956521739
1443,revenue,1.8194444444444444
1444,08 revenue,1.8194444444444444
1445,12 revenue,1.8194444444444444
1446,10 revenue,1.8194444444444444
1447,products,1.819277108433735
1448,income,1.8181818181818181
1449,full,1.8181818181818181
1450,disclosures,1.8148148148148149
1451,indemnification,1.8148148148148149
1452,amortization,1.8148148148148149
1453,rights,1.813953488372093
1454,rent,1.8125
1455,requirements,1.8076923076923077
1456,judgments,1.8076923076923077
1457,decrease,1.8076923076923077
1458,2016 notes,1.8
1459,exchange,1.8
1460,presented,1.8
1461,designed,1.8
1462,initiated,1.8
1463,delivery,1.8
1464,remaining $1,1.8
1465,arrangements,1.8
1466,paying $2,1.8
1467,a1at,1.8
1468,remaining 250,1.8
1469,2017 notes,1.8
1470,paying,1.8
1471,cornell,1.8
1472,notes,1.8
1473,report,1.794871794871795
1474,incurred,1.7906976744186047
1475,including,1.7887323943661972
1476,including $1,1.7887323943661972
1477,including $0,1.7887323943661972
1478,stockholders,1.7857142857142858
1479,applicable,1.7857142857142858
1480,deferred,1.7857142857142858
1481,completed,1.7857142857142858
1482,equity,1.7826086956521738
1483,year,1.78
1484,entered,1.7719298245614035
1485,date,1.7712418300653594
1486,advancing,1.7692307692307692
1487,method,1.7647058823529411
1488,low,1.7647058823529411
1489,arrangement,1.7619047619047619
1490,unit,1.76
1491,primarily,1.7575757575757576
1492,awards,1.7555555555555555
1493,basis,1.7532467532467533
1494,liability,1.75
1495,fixed,1.75
1496,purchased,1.75
1497,section,1.75
1498,collaboration,1.75
1499,patents,1.75
1500,benefits,1.75
1501,goodwill,1.7432432432432432
1502,patients,1.736842105263158
1503,32 patients,1.736842105263158
1504,asu,1.734375
1505,1 project,1.7333333333333334
1506,entities,1.7272727272727273
1507,meet,1.7272727272727273
1508,exercises,1.7272727272727273
1509,acquisition,1.723529411764706
1510,commercialization,1.7222222222222223
1511,preliminary,1.7142857142857142
1512,performing,1.7142857142857142
1513,licenses,1.7142857142857142
1514,pending,1.7142857142857142
1515,standalone,1.7142857142857142
1516,meeting,1.7142857142857142
1517,highly,1.7142857142857142
1518,observe,1.7142857142857142
1519,deficiency,1.7058823529411764
1520,estimated,1.7
1521,approved,1.6956521739130435
1522,adjustments,1.6923076923076923
1523,pursuant,1.6923076923076923
1524,indefinite,1.6923076923076923
1525,15 pursuant,1.6923076923076923
1526,factors,1.6875
1527,modified,1.6875
1528,total,1.675
1529,exercise,1.6744186046511629
1530,portfolio,1.6666666666666667
1531,vote,1.6666666666666667
1532,december31,1.6666666666666667
1533,markets,1.6666666666666667
1534,active,1.6666666666666667
1535,payroll,1.6666666666666667
1536,differ,1.6666666666666667
1537,day,1.6666666666666667
1538,target,1.6666666666666667
1539,breach,1.6666666666666667
1540,assistance,1.6666666666666667
1541,obligation,1.6666666666666667
1542,facility,1.6666666666666667
1543,baculovirus,1.6666666666666667
1544,expires,1.6666666666666667
1545,claims,1.6470588235294117
1546,action,1.6428571428571428
1547,vector,1.64
1548,rate,1.6363636363636365
1549,receive,1.6363636363636365
1550,risk,1.6363636363636365
1551,post,1.6363636363636365
1552,table,1.6363636363636365
1553,presentation,1.625
1554,indication,1.625
1555,licensing,1.625
1556,comparison,1.625
1557,viral,1.625
1558,attributable,1.625
1559,business,1.6216216216216217
1560,milestones,1.619047619047619
1561,vesting,1.6176470588235294
1562,annapurna,1.6098484848484849
1563,support,1.606060606060606
1564,inputs,1.6
1565,sufficient,1.6
1566,effect,1.6
1567,earlier,1.6
1568,directly,1.6
1569,indications,1.6
1570,france,1.6
1571,eye,1.6
1572,adopt,1.6
1573,address,1.6
1574,collaborations,1.6
1575,contributed,1.6
1576,performed,1.59375
1577,sale,1.5901639344262295
1578,litigation,1.588235294117647
1579,technologies,1.5833333333333333
1580,discounts,1.5714285714285714
1581,consisting,1.5714285714285714
1582,agreed,1.5714285714285714
1583,anticipate,1.5714285714285714
1584,require,1.5714285714285714
1585,liabilities,1.5701754385964912
1586,agreement,1.5695792880258899
1587,offer,1.5666666666666667
1588,make,1.5625
1589,management,1.5606060606060606
1590,include,1.5555555555555556
1591,subjects,1.5555555555555556
1592,resources,1.5555555555555556
1593,indicative,1.5555555555555556
1594,advance,1.542857142857143
1595,000 advance,1.542857142857143
1596,terminated,1.5416666666666667
1597,performance,1.5405405405405406
1598,general,1.5303030303030303
1599,24 general,1.5303030303030303
1600,risks,1.5294117647058822
1601,recorded,1.504
1602,results,1.5
1603,derived,1.5
1604,effective,1.5
1605,leases,1.5
1606,comparable,1.5
1607,involved,1.5
1608,officers,1.5
1609,actions,1.5
1610,successful,1.5
1611,administered,1.5
1612,effort,1.5
1613,legal,1.5
1614,debilitating,1.5
1615,evaluates,1.5
1616,adjustment,1.5
1617,indicators,1.5
1618,default,1.5
1619,adeno,1.5
1620,premium,1.5
1621,exclusivity,1.5
1622,principal,1.5
1623,ind,1.5
1624,tap,1.5
1625,extension,1.5
1626,originally,1.5
1627,files,1.5
1628,fails,1.5
1629,shares,1.4957264957264957
1630,375 shares,1.4957264957264957
1631,918 shares,1.4957264957264957
1632,383 shares,1.4957264957264957
1633,246 shares,1.4957264957264957
1634,940 shares,1.4957264957264957
1635,656 shares,1.4957264957264957
1636,425 shares,1.4957264957264957
1637,856 shares,1.4957264957264957
1638,000 shares,1.4957264957264957
1639,level,1.486842105263158
1640,level,1.486842105263158
1641,level,1.486842105263158
1642,level,1.486842105263158
1643,7 years,1.4814814814814814
1644,0 years,1.4814814814814814
1645,9 years,1.4814814814814814
1646,years,1.4814814814814814
1647,4 years,1.4814814814814814
1648,8 years,1.4814814814814814
1649,3 years,1.4814814814814814
1650,2 years,1.4814814814814814
1651,10 years,1.4814814814814814
1652,exercised,1.48
1653,fair,1.4787644787644787
1654,events,1.4782608695652173
1655,share,1.4767441860465116
1656,assumptions,1.4761904761904763
1657,exist,1.4705882352941178
1658,amount,1.4696969696969697
1659,issuance,1.469387755102041
1660,defined,1.4666666666666666
1661,maturities,1.4666666666666666
1662,2014 plan,1.462686567164179
1663,plan,1.462686567164179
1664,goals,1.4615384615384615
1665,discussed,1.4615384615384615
1666,noted,1.4615384615384615
1667,option,1.4573643410852712
1668,equipment,1.4565217391304348
1669,treated,1.4545454545454546
1670,valued,1.4545454545454546
1671,rsus,1.4523809523809523
1672,reserved,1.4444444444444444
1673,entire $1,1.4444444444444444
1674,fully,1.4444444444444444
1675,adjusted,1.4444444444444444
1676,bankruptcy,1.4444444444444444
1677,adopted,1.4444444444444444
1678,measured,1.44
1679,grant,1.4375
1680,conditions,1.434782608695652
1681,excluded,1.434782608695652
1682,inserm,1.434782608695652
1683,terms,1.4310344827586208
1684,improvements,1.4285714285714286
1685,held,1.4285714285714286
1686,allocated,1.4210526315789473
1687,investments,1.4090909090909092
1688,shareholder,1.4
1689,companies,1.4
1690,decided,1.4
1691,lives,1.4
1692,ataxia,1.4
1693,alpha,1.4
1694,australian,1.4
1695,continues,1.4
1696,cnv,1.4
1697,paid,1.393939393939394
1698,consulting,1.3888888888888888
1699,termination,1.3870967741935485
1700,expected,1.3846153846153846
1701,fund,1.3846153846153846
1702,regenxbio,1.3846153846153846
1703,company,1.38159509202454
1704,pay,1.375
1705,measurements,1.375
1706,forward,1.375
1707,details,1.375
1708,party,1.36
1709,depreciation,1.36
1710,distribution,1.3571428571428572
1711,circumstances,1.3529411764705883
1712,increase,1.35
1713,deliverables,1.3461538461538463
1714,analysis,1.3414634146341464
1715,estimates,1.3414634146341464
1716,effects,1.3333333333333333
1717,overview,1.3333333333333333
1718,caused,1.3333333333333333
1719,dose,1.3333333333333333
1720,commonly,1.3333333333333333
1721,director,1.3333333333333333
1722,purchases,1.3333333333333333
1723,changed,1.3333333333333333
1724,carrying,1.3333333333333333
1725,pre,1.3333333333333333
1726,represents,1.3333333333333333
1727,manner,1.3333333333333333
1728,discount,1.3333333333333333
1729,clarifies,1.3333333333333333
1730,invalid,1.3333333333333333
1731,wamd,1.3333333333333333
1732,conduct,1.3333333333333333
1733,employees,1.328125
1734,impact,1.3225806451612903
1735,recognize,1.3214285714285714
1736,recognize $6,1.3214285714285714
1737,recognize $1,1.3214285714285714
1738,amended,1.3111111111111111
1739,regeneron,1.3047619047619048
1740,entity,1.2941176470588236
1741,principle,1.2857142857142858
1742,evaluation,1.2857142857142858
1743,holder,1.2857142857142858
1744,exercising,1.2857142857142858
1745,adjust,1.2857142857142858
1746,increases,1.2857142857142858
1747,claim,1.2857142857142858
1748,part,1.2777777777777777
1749,months,1.2758620689655173
1750,36 months,1.2758620689655173
1751,aav,1.2666666666666666
1752,recognized,1.2580645161290323
1753,included 359,1.2537313432835822
1754,included,1.2537313432835822
1755,included $1,1.2537313432835822
1756,included $0,1.2537313432835822
1757,time,1.25
1758,anti,1.25
1759,scope,1.25
1760,denied,1.25
1761,care,1.25
1762,022 anti,1.25
1763,treatment,1.2444444444444445
1764,editas,1.236842105263158
1765,standard,1.2325581395348837
1766,quarter,1.2307692307692308
1767,substantially,1.2307692307692308
1768,quarter,1.2307692307692308
1769,required,1.2295081967213115
1770,advm,1.2291666666666667
1771,proceed,1.2222222222222223
1772,royalties,1.21875
1773,estimate,1.2173913043478262
1774,nature,1.2105263157894737
1775,commercialize,1.2083333333333333
1776,approximately 13,1.2
1777,approximately 4,1.2
1778,approximately $130,1.2
1779,approximately $8,1.2
1780,measurement,1.2
1781,pipeline,1.2
1782,approximately 11,1.2
1783,amortized,1.2
1784,triggered,1.2
1785,chairman,1.2
1786,approximately $20,1.2
1787,route,1.2
1788,approximately 2,1.2
1789,13 measurement,1.2
1790,sources,1.1904761904761905
1791,disclosure,1.1875
1792,number,1.1851851851851851
1793,directors,1.1851851851851851
1794,probable,1.1851851851851851
1795,expect,1.1842105263157894
1796,determined,1.183673469387755
1797,concluded,1.1818181818181819
1798,ava,1.1818181818181819
1799,revenues,1.1818181818181819
1800,60 days,1.1818181818181819
1801,30 days,1.1818181818181819
1802,days,1.1818181818181819
1803,6 million,1.1795841209829867
1804,3 million,1.1795841209829867
1805,0 million,1.1795841209829867
1806,4 million,1.1795841209829867
1807,8 million,1.1795841209829867
1808,1 million,1.1795841209829867
1809,9 million,1.1795841209829867
1810,7 million,1.1795841209829867
1811,5 million,1.1795841209829867
1812,2 million,1.1795841209829867
1813,85 million,1.1795841209829867
1814,complete,1.1785714285714286
1815,continue,1.1777777777777778
1816,uncertainties,1.1764705882352942
1817,sell,1.173913043478261
1818,develop,1.1724137931034482
1819,developing,1.1666666666666667
1820,contained,1.1666666666666667
1821,added,1.1666666666666667
1822,collaborative,1.1666666666666667
1823,marketing,1.1538461538461537
1824,country,1.1470588235294117
1825,summary,1.1428571428571428
1826,step,1.1428571428571428
1827,expire,1.1428571428571428
1828,anniversary,1.1428571428571428
1829,settlement,1.1333333333333333
1830,generated,1.125
1831,collaborate,1.125
1832,operations,1.1229508196721312
1833,regents,1.1162790697674418
1834,january 29,1.1111111111111112
1835,january 2015,1.1111111111111112
1836,hierarchy,1.1111111111111112
1837,january 13,1.1111111111111112
1838,january 2016,1.1111111111111112
1839,timing,1.108695652173913
1840,contracts,1.1071428571428572
1841,evaluating,1.105263157894737
1842,calculated,1.105263157894737
1843,advances,1.105263157894737
1844,topic,1.1
1845,topic,1.1
1846,needed,1.0909090909090908
1847,accounted,1.0833333333333333
1848,classified,1.0769230769230769
1849,payable,1.0769230769230769
1850,terminate,1.0579710144927537
1851,follow,1.0476190476190477
1852,form 10,1.0476190476190477
1853,2014 espp,1.0476190476190477
1854,form,1.0476190476190477
1855,subject,1.0465116279069768
1856,obtain,1.0416666666666667
1857,result,1.0350877192982457
1858,december,1.027027027027027
1859,december,1.027027027027027
1860,december,1.027027027027027
1861,december,1.027027027027027
1862,item1,1.0
1863,unaudited,1.0
1864,thousands,1.0
1865,march 31,1.0
1866,incorporated,1.0
1867,delaware,1.0
1868,july,1.0
1869,headquartered,1.0
1870,california,1.0
1871,discovering,1.0
1872,medicines,1.0
1873,chronic,1.0
1874,inception,1.0
1875,devoted,1.0
1876,expands,1.0
1877,engages,1.0
1878,privately,1.0
1879,shareholders,1.0
1880,contributors,1.0
1881,acting,1.0
1882,representative,1.0
1883,acquire,1.0
1884,converted,1.0
1885,relate,1.0
1886,rounded,1.0
1887,nearest,1.0
1888,holders,1.0
1889,case,1.0
1890,contributor,1.0
1891,connection,1.0
1892,close,1.0
1893,occurred,1.0
1894,execution,1.0
1895,exceptions,1.0
1896,approve,1.0
1897,failure,1.0
1898,communicated,1.0
1899,writing,1.0
1900,board,1.0
1901,withdrawn,1.0
1902,offerings,1.0
1903,underwriters,1.0
1904,commissions,1.0
1905,march 2015,1.0
1906,resulted,1.0
1907,prepared,1.0
1908,accordance,1.0
1909,gaap,1.0
1910,sec,1.0
1911,rules,1.0
1912,footnotes,1.0
1913,omitted,1.0
1914,reflect,1.0
1915,read,1.0
1916,conjunction,1.0
1917,2015 filed,1.0
1918,preparation,1.0
1919,consistent,1.0
1920,note,1.0
1921,customers,1.0
1922,supersedes,1.0
1923,asc 605,1.0
1924,depict,1.0
1925,transfer,1.0
1926,goods,1.0
1927,reflects,1.0
1928,entitled,1.0
1929,uncertainty,1.0
1930,fulfill,1.0
1931,july,1.0
1932,august 2014,1.0
1933,concern,1.0
1934,subtopic 205,1.0
1935,ability,1.0
1936,evaluate,1.0
1937,perform,1.0
1938,type,1.0
1939,alleviate,1.0
1940,amends,1.0
1941,classification,1.0
1942,february 2016,1.0
1943,aimed,1.0
1944,transparent,1.0
1945,lessees,1.0
1946,asset,1.0
1947,march,1.0
1948,9 simplifies,1.0
1949,aspects,1.0
1950,reviewed,1.0
1951,hold,1.0
1952,maturity,1.0
1953,sold,1.0
1954,investment,1.0
1955,corroborated,1.0
1956,supported,1.0
1957,input,1.0
1958,assessment,1.0
1959,significance,1.0
1960,addition,1.0
1961,comparisons,1.0
1962,certificate,1.0
1963,deposit,1.0
1964,bid/,1.0
1965,quotes,1.0
1966,transfers,1.0
1967,reimburse,1.0
1968,obligated,1.0
1969,achievement,1.0
1970,achieved,1.0
1971,commitments,1.0
1972,determinable,1.0
1973,guarantees,1.0
1974,indemnifications,1.0
1975,variety,1.0
1976,representations,1.0
1977,warranties,1.0
1978,exposure,1.0
1979,unknown,1.0
1980,made,1.0
1981,defend,1.0
1982,occurrences,1.0
1983,limits,1.0
1984,serving,1.0
1985,request,1.0
1986,capacities,1.0
1987,minimal,1.0
1988,range,1.0
1989,met,1.0
1990,filed,1.0
1991,behalf,1.0
1992,persons,1.0
1993,july,1.0
1994,june,1.0
1995,allege,1.0
1996,things,1.0
1997,prospects,1.0
1998,attorneys,1.0
1999,state,1.0
2000,county,1.0
2001,merit,1.0
2002,intend,1.0
2003,defending,1.0
2004,assurance,1.0
2005,defense,1.0
2006,cover,1.0
2007,predict,1.0
2008,matters,1.0
2009,permits,1.0
2010,types,1.0
2011,consultants,1.0
2012,authorized,1.0
2013,july,1.0
2014,establishment,1.0
2015,difference,1.0
2016,weighted,1.0
2017,nonemployees,1.0
2018,entitle,1.0
2019,april,1.0
2020,vested,1.0
2021,black,1.0
2022,earned,1.0
2023,estimating,1.0
2024,code,1.0
2025,participants,1.0
2026,defer,1.0
2027,portion,1.0
2028,dividing,1.0
2029,computed,1.0
2030,antidilutive,1.0
2031,computation,1.0
2032,operation,1.0
2033,discussion,1.0
2034,march,1.0
2035,meaning,1.0
2036,set,1.0
2037,leveraged,1.0
2038,focusing,1.0
2039,lei,1.0
2040,australia,1.0
2041,june,1.0
2042,additionally,1.0
2043,conducted,1.0
2044,retina,1.0
2045,majority,1.0
2046,half,1.0
2047,inform,1.0
2048,negotiation,1.0
2049,november,1.0
2050,working,1.0
2051,evaluated,1.0
2052,juvenile,1.0
2053,xlrs,1.0
2054,cvd,1.0
2055,red,1.0
2056,contracted,1.0
2057,cros,1.0
2058,carry,1.0
2059,prepare,1.0
2060,unable,1.0
2061,forced,1.0
2062,delay,1.0
2063,reduce,1.0
2064,eliminate,1.0
2065,multi,1.0
2066,account,1.0
2067,straight,1.0
2068,applied,1.0
2069,receivable,1.0
2070,cost,1.0
2071,acquiring,1.0
2072,utilities,1.0
2073,expensed,1.0
2074,delivered,1.0
2075,expended,1.0
2076,communications,1.0
2077,accrual,1.0
2078,probability,1.0
2079,success,1.0
2080,expectations,1.0
2081,refunds,1.0
2082,depend,1.0
2083,reduction,1.0
2084,reimbursement,1.0
2085,audit,1.0
2086,extent,1.0
2087,affect,1.0
2088,base,1.0
2089,reasonable,1.0
2090,invest,1.0
2091,assess,1.0
2092,comprised,1.0
2093,liquidity,1.0
2094,order,1.0
2095,build,1.0
2096,pursue,1.0
2097,initiation,1.0
2098,progress,1.0
2099,outcome,1.0
2100,seeking,1.0
2101,food,1.0
2102,fda,1.0
2103,expand,1.0
2104,preparing,1.0
2105,manufacture,1.0
2106,degree,1.0
2107,prosecuting,1.0
2108,enforcing,1.0
2109,enter,1.0
2110,emergence,1.0
2111,prefer,1.0
2112,0million,1.0
2113,3million,1.0
2114,june,1.0
2115,dated,1.0
2116,april,1.0
2117,par,1.0
2118,refer,1.0
2119,note 3,1.0
2120,completion,1.0
2121,wednesday,1.0
2122,aavl,1.0
2123,thursday,1.0
2124,opinion,1.0
2125,longer,1.0
2126,facts,1.0
2127,recovery,1.0
2128,comparing,1.0
2129,forecast,1.0
2130,abandonment,1.0
2131,occur,1.0
2132,tested,1.0
2133,aware,1.0
2134,obtained,1.0
2135,point,1.0
2136,abandoned,1.0
2137,excess,1.0
2138,asc,1.0
2139,ireland,1.0
2140,apply,1.0
2141,receiving,1.0
2142,founders,1.0
2143,attributed,1.0
2144,assuming,1.0
2145,dividends,1.0
2146,asc 805,1.0
2147,acquirer,1.0
2148,existence,1.0
2149,qualify,1.0
2150,valuing,1.0
2151,components,1.0
2152,summarized,1.0
2153,promotion,1.0
2154,friedreich,1.0
2155,nominal,1.0
2156,deductible,1.0
2157,businesses,1.0
2158,executives,1.0
2159,frequently,1.0
2160,determine,1.0
2161,change,1.0
2162,short,1.0
2163,couple,1.0
2164,plant,1.0
2165,earnings,1.0
2166,corroboration,1.0
2167,discover,1.0
2168,extended,1.0
2169,responsible,1.0
2170,eligible,1.0
2171,mid,1.0
2172,profits,1.0
2173,respect,1.0
2174,expiration,1.0
2175,end,1.0
2176,situations,1.0
2177,convenience,1.0
2178,totality,1.0
2179,cured,1.0
2180,reorganization,1.0
2181,dissolution,1.0
2182,validity,1.0
2183,enforceability,1.0
2184,ann,1.0
2185,department,1.0
2186,1 antitrypsin,1.0
2187,allergens,1.0
2188,utilize,1.0
2189,institution,1.0
2190,gmp,1.0
2191,achieve,1.0
2192,crystal,1.0
2193,consultant,1.0
2194,october,1.0
2195,import,1.0
2196,april,1.0
2197,aavrh10,1.0
2198,benefited,1.0
2199,investissement,1.0
2200,facilitate,1.0
2201,intended,1.0
2202,finance,1.0
2203,recruitment,1.0
2204,august 2015,1.0
2205,drawn,1.0
2206,scheduled,1.0
2207,september 30,1.0
2208,note 6,1.0
2209,accrues,1.0
2210,invoiced,1.0
2211,motion,1.0
2212,dismiss,1.0
2213,essentially,1.0
2214,plaintiff,1.0
2215,dismissed,1.0
2216,stay,1.0
2217,august 2016,1.0
2218,credited,1.0
2219,virus,1.0
2220,parties,1.0
2221,participation,1.0
2222,clarification,1.0
2223,april2016,1.0
2224,narrow,1.0
2225,repay,1.0
2226,investigational,1.0
2227,served,1.0
2228,withdraw,1.0
2229,challenge,1.0
2230,july,1.0
2231,5 times,1.0
2232,file,1.0
2233,october,1.0
2234,president,1.0
2235,concurrently,1.0
2236,20 item2,1.0
2237,minimize,1.0
2238,laser,1.0
2239,surgical,1.0
2240,large,1.0
2241,2016 filed,1.0
2242,immaterial,1.0
2243,provisions,1.0
2244,methods,1.0
2245,providing,1.0
2246,april,1.0
2247,improvement,1.0
2248,preliminarily,1.0
2249,transparency,1.0
2250,comparability,1.0
2251,june,1.0
2252,november,1.0
2253,amendments,1.0
2254,temporary,1.0
2255,cases,1.0
2256,september,1.0
2257,treating,1.0
2258,export,1.0
2259,fields,1.0
2260,extend,1.0
2261,times,1.0
2262,reaching,1.0
2263,stages,1.0
2264,developed,1.0
2265,sublicensees,1.0
2266,prosecution,1.0
2267,finally,1.0
2268,insolvent,1.0
2269,unenforceable,1.0
2270,february 23,1.0
2271,extending,1.0
2272,place,1.0
2273,reimbursements,1.0
2274,msa,1.0
2275,disputes,1.0
2276,decision,1.0
2277,043 suitable,1.0
2278,complies,1.0
2279,implementing,1.0
2280,lapse,1.0
2281,invalidation,1.0
2282,reason,1.0
2283,affiliates,1.0
2284,commence,1.0
2285,regenexbio,1.0
2286,licensors,1.0
2287,declare,1.0
2288,render,1.0
2289,april,1.0
2290,october,1.0
2291,extensions,1.0
2292,countries,1.0
2293,world,1.0
2294,perpetual,1.0
2295,voluntary,1.0
2296,escalation,1.0
2297,parking,1.0
2298,march 16,1.0
2299,settle,1.0
2300,remainder,1.0
2301,insurers,1.0
2302,deny,1.0
2303,assign,1.0
2304,admission,1.0
2305,fault,1.0
2306,wrongdoing,1.0
2307,defendant,1.0
2308,estimable,1.0
2309,march,1.0
2310,leveraging,1.0
2311,specifically,1.0
2312,led,1.0
2313,team,1.0
2314,aflibercept,1.0
2315,commercializing,1.0
2316,vendors,1.0
2317,subsequently,1.0
2318,compared,1.0
